HEALTH● LOWAug 12 · Aug 12, 2026, 2:58 PM
Acumen anticipates mid-2027 IND filing for lead EBD candidate while keeping Phase II ALTITUDE-AD topline results on track for late 2026
Seeking Alpha Tech
Acumen anticipates filing an Investigational New Drug (IND) application for its lead EBD candidate by mid-2027, with Phase II ALTITUDE-AD trial results expected in late 2026. This announcement details key milestones in the development of a potential new medical treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH26m agoGenmab rises, Corcept falls on late-stage antibody-conjugate data for ovarian cancerSeeking Alpha TechHEALTH30m agoScreening Linked to Fewer CRC Deaths in Basque Adults 50–69Human ProgressHEALTH37m agoMalaria Has Fallen Sharply on Bioko IslandHuman ProgressHEALTH38m agoGlobal Adolescent Birth Rates Fell Since 1990Human Progress